Reconsidering Standard of Care for Hypercortisolism
Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.
Read More
Mifeprestone for Treatment of Hypercortisolism
Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.
Read More
Engaging Primary Care Clinicians in Screening for Hypercortisolism
Medical experts explore why findings from this study are crucial for clinicians managing diabetes, particularly those in primary care settings, and how these insights can impact their approach to patient care.
Read More
Coexisting Cardiometabolic Conditions and Hypercortisolism
Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.
Read More
Diabetes Dialogue: FLOW Trial and Semaglutide's Benefit in Chronic Kidney Disease
May 25th 2024Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.
Read More